Welcome to our dedicated page for AETHLON MEDICAL news (Ticker: AEMD), a resource for investors and traders seeking the latest updates and insights on AETHLON MEDICAL stock.
Aethlon Medical Inc. (Nasdaq: AEMD) is an innovative medical technology company dedicated to addressing unmet medical needs in health and biodefense. The company's core focus is on developing the Hemopurifier®, a clinical-stage therapeutic device designed to combat cancer and life-threatening viral infections, and for use in organ transplantation. Aethlon’s proprietary technology, the Aethlon ADAPT™ platform, provides the foundation for a new class of therapeutics that target the selective removal of disease-enabling particles from the entire circulatory system.
The Hemopurifier®, designated as a breakthrough device by the FDA, has demonstrated broad-spectrum capabilities against exosomes that contribute to the progression of cancer and viruses like HIV and Hepatitis C. Recent developments include ongoing research and clinical trials to evaluate the device's safety and efficacy in removing harmful exosomes and viruses from blood. These trials are taking place in India and Australia, targeting patients with solid tumors who have stable or progressive disease during anti-PD-1 monotherapy treatment, such as Keytruda® or Opdivo®.
Financially, Aethlon Medical reported a cash balance of approximately $8.0 million as of the end of 2023. The company also announced a public offering expected to raise around $4.7 million to support its clinical trials, research, and other corporate needs. The company's leadership, including Interim CEO and CFO Jim Frakes, is committed to advancing the Hemopurifier® and exploring new applications in oncology and infectious diseases.
Partnerships are a crucial aspect of Aethlon’s strategy. The company recently entered into a Materials Transfer Agreement with Santersus AG to explore potential synergies between the Hemopurifier® and Santersus' NucleoCapture devices for the treatment of cancer and organ transplantation. This collaboration aims to enhance the effectiveness of both technologies by combining their capabilities to remove specific harmful agents from the blood.
Overall, Aethlon Medical Inc. is at the forefront of developing groundbreaking medical devices aimed at improving outcomes for patients with severe health conditions, making significant strides in the fields of cancer and infectious diseases.
For more information, visit Aethlon Medical.
Aethlon Medical, Inc. (AEMD) reported financial results for Q2 2022, with a net loss of approximately $3.8 million, a significant increase from $2.0 million in Q2 2021. Operating expenses rose to $3.67 million, up 71% year-over-year. The company has terminated its U.S. COVID-19 trial and head and neck cancer safety trial due to low patient enrollment, reallocating funds to advance the Hemopurifier in oncology research. As of September 30, 2022, Aethlon had a cash balance of $19.6 million and plans to launch a new oncology trial while engaging a new CRO in the U.S. and Australia.
Aethlon Medical (Nasdaq: AEMD) will announce its second-quarter financial results for the period ending September 30, 2022, on November 14, 2022, at 4:15 p.m. EST. A conference call will follow at 4:30 p.m. EST to discuss the results and corporate developments. The Hemopurifier, a breakthrough device, is being evaluated for treating cancer and infectious diseases. Notably, it has shown potential in removing harmful exosomes related to cancer and treating COVID-19 patients, demonstrating effectiveness in binding and removing the SARS-CoV-2 virus.
Aethlon Medical (Nasdaq: AEMD) announced participation in two key investor conferences in September 2022. The first is the H.C. Wainwright 24th Annual Global Investment Conference from Sept. 12-14, where pre-recorded presentations will be available on-demand from Sept. 12, 7:00 a.m. EDT. The second is the Life Sciences Investor Forum on Sept. 15, featuring a live presentation at 2 p.m. EDT. The presentations will highlight Aethlon's innovative Hemopurifier for treating cancer and infectious diseases, designed to remove harmful components from the bloodstream.
Aethlon Medical (AEMD) reported its financial results for the first quarter ending June 30, 2022, highlighting a cash balance of approximately $14.9 million. The company experienced a 30% increase in operating expenses, totaling around $2.91 million, primarily due to higher general and administrative costs. Revenue dropped from $132,000 in Q1 2021 to zero in the same period of 2022, resulting in a net loss of approximately $2.9 million. Aethlon is advancing clinical trials for its Hemopurifier® device targeting COVID-19 and cancer, and plans to assess its effectiveness against the monkeypox virus.
Aethlon Medical, Inc. (Nasdaq: AEMD) will announce its financial results for the first quarter ending June 30, 2022, on August 9, 2022, at 4:15 p.m. EST. A conference call will follow at 4:30 p.m. EST to discuss the results and recent corporate developments. Interested parties can register for the call or dial in. The Hemopurifier, Aethlon's main product, has FDA Breakthrough Device designation for treating cancer and infectious diseases, showing promise in reducing harmful exosomes and viruses from blood, including SARS-CoV-2.
Aethlon Medical (AEMD) announced a peer-reviewed article published in PLOS ONE, showcasing that its GNA affinity resin in the Hemopurifier effectively captures seven SARS-CoV-2 variants, with efficacy ranging from 53% to 89%. CEO Charles J. Fisher emphasized the potential of the Hemopurifier in addressing emerging COVID-19 variants. The company is currently conducting an Early Feasibility Study involving 40 severe COVID-19 patients, and recently received FDA protocol amendment approval to eliminate prior dialysis treatment, which may expedite patient enrollment.
Aethlon Medical (AEMD) announced FDA approval for a protocol amendment in its ongoing clinical trial for the Aethlon Hemopurifier® targeting severe COVID-19 patients. The amendment removes the requirement for patients to have a dialysis catheter, potentially accelerating patient enrollment. The Hemopurifier is designed to filter out life-threatening viruses and harmful exosomes from blood and is being evaluated in a feasibility study involving up to 40 patients across multiple clinical sites. The company aims to enhance patient access to this innovative therapy.
Aethlon Medical (Nasdaq: AEMD) reported financials for the fiscal year ended March 31, 2022, revealing a cash balance of $17.1 million and a revenue of approximately $294,000, a decline from $659,000 in the prior year. Operating expenses rose to $10.72 million from $8.55 million, leading to a net loss of $10.4 million. The company is advancing the Hemopurifier for COVID-19 treatment and cancer, enrolling patients across multiple sites. Recent developments include ethics approval for a clinical trial in India and the appointment of Angela Rossetti to the Board.
Aethlon Medical, Inc. (Nasdaq: AEMD) will announce its financial results for the fiscal year ending March 31, 2022, on June 28, 2022, at 4:15 p.m. EST. A conference call will follow at 4:30 p.m. EST to discuss these results and recent corporate developments. The Hemopurifier, Aethlon's lead technology, is designed to treat cancer and infectious diseases, holding FDA Breakthrough Device designation for advanced cancer therapy and addressing life-threatening viruses. A replay of the conference will be available for a month post-call.
FAQ
What is the current stock price of AETHLON MEDICAL (AEMD)?
What is the market cap of AETHLON MEDICAL (AEMD)?
What is Aethlon Medical Inc.?
What is the Hemopurifier®?
What are the recent developments for Aethlon Medical?
Who is leading Aethlon Medical?
What are exosomes and why are they important?
How is Aethlon Medical funded?
What collaborations does Aethlon Medical have?
What makes the Hemopurifier® unique?
Where can I find more information about Aethlon Medical?
What are the financial highlights of Aethlon Medical?
